EC Number   |
Application |
Reference |
|---|
    1.3.1.9 | analysis |
construction of tetracysteine-tagged enzyme variants carrying the tag at the N-terminus, C-terminus, or both N- and C-terminus. All the tetracysteine-tagged FabI enzymes have high enzyme activities while the enhanced green fluorescent protein-tagged FabI exhaustively loses the activity. The binding between 4',5'-bis(1,3,2-dithioarsolan-2-yl)fuorescein, i.e. FlAsH reagent and tetracysteine motif is stable against high pressure, high field strength, high temperature, and ultrasound. A capillary zone electrophoresis system equipped with a laser-induced fluorescence detector has a detection limit of 10-16 M for the labeled proteins |
724490 |
| 1.3.1.9 | analysis |
development of a simple thermal shift assay, which does not use ACP-linked substrates, to determine the binding ability of triclosan to the enzyme's active site |
742918 |
| 1.3.1.9 | drug development |
InhA is an attractive target for the development of drugs against tuberculosis |
-, 712422 |
| 1.3.1.9 | drug development |
the bacterial enoyl-ACP reductase is a target for antibacterial drug development |
-, 711351 |
| 1.3.1.9 | medicine |
anti-malarial target |
676367 |
| 1.3.1.9 | medicine |
antibacterial target |
671150, 671166, 672553, 672556, 673193, 675303 |
| 1.3.1.9 | medicine |
antimalarial target |
675299 |
| 1.3.1.9 | medicine |
de novo fatty acid biosynthetic components encoded in Francisella tularensis are transcriptionally active during infection in the mouse model of tularemia |
-, 725286 |
| 1.3.1.9 | medicine |
enoyl-acyl carrier protein reductase from Plasmodium falciparum is an important target for anti-malarial agents |
697740 |
| 1.3.1.9 | medicine |
enoyl-acyl carrier protein reductase inhibitors turn out to be clinically useful antimicrobials |
697217 |
